Fibronectin inhibits the cytotoxic effect of ricin A chain on endothelial cells

被引:21
作者
Baluna, R
Ghetie, V
OppenheimerMarks, N
Vitetta, ES
机构
[1] UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235
[2] UNIV TEXAS,SW MED CTR,CTR CANC IMMUNOBIOL,DALLAS,TX 75235
[3] UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235
来源
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY | 1996年 / 18卷 / 6-7期
关键词
monoclonal antibody; endothelial cells; toxin;
D O I
10.1016/S0192-0561(96)00043-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We have previously reported that after in vitro treatment with deglycosylated ricin A chain (dgRTA), human umbilical vein endothelial cells (HUVECs) undergo changes in morphology including cell rounding and disruption of monolayers. The present studies were carried out to determine whether these changes were related to the disruptions in endothelial cell (EC) interactions with the extracellular matrix. To this end, we examined the effect of dgRTA on HUVECs in the presence of fibronectin (Fn), an extracellular matrix protein, which plays a role in the maintenance of vascular integrity. The addition of exogenous Fn greatly inhibited dgRTA-mediated morphological changes in HUVEC monolayers, dgRTA-mediated inhibition of [H-3]thymidine incorporation in HUVECs and the binding of I-125-dgRTA to HUVECs. Should the same phenomenon occur with RTA-based immunotoxins (ITs) in vivo, this might shed light on the development of dgRTA-mediated vascular leak syndrome (VLS) during IT therapy and provide new insights into how to decrease this toxicity in patients. Copyright (C) 1996 International Society for Immunopharmacology
引用
收藏
页码:355 / 361
页数:7
相关论文
共 22 条
[1]   IDENTIFICATION AND CHARACTERIZATION OF CELL-SUBSTRATUM ADHESION RECEPTORS ON CULTURED HUMAN-ENDOTHELIAL CELLS [J].
ALBELDA, SM ;
DAISE, M ;
LEVINE, EM ;
BUCK, CA .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (06) :1992-2002
[2]  
AMLOT PL, 1993, BLOOD, V82, P2624
[3]   ENDOTHELIAL-CELL ADHESIVE RECEPTORS [J].
DEJANA, E .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1993, 21 :S18-S21
[4]  
FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0
[5]   CLINICAL-TRIALS OF TARGETED TOXINS [J].
FRANKEL, AE ;
TAGGE, EP ;
WILLINGHAM, MC .
SEMINARS IN CANCER BIOLOGY, 1995, 6 (05) :307-317
[6]  
GHETIE MA, 1988, CANCER RES, V48, P2610
[7]   ANTI-B4-BLOCKED RICIN - A PHASE-I TRIAL OF 7-DAY CONTINUOUS INFUSION IN PATIENTS WITH B-CELL NEOPLASMS [J].
GROSSBARD, ML ;
LAMBERT, JM ;
GOLDMACHER, VS ;
SPECTOR, NL ;
KINSELLA, J ;
ELISEO, L ;
CORAL, F ;
TAYLOR, JA ;
BLATTLER, WA ;
EPSTEIN, CL ;
NADLER, LM .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (04) :726-737
[8]  
Kuan CT, 1995, CLIN CANCER RES, V1, P1589
[9]   THE ROLE OF INTEGRINS IN THE MAINTENANCE OF ENDOTHELIAL MONOLAYER INTEGRITY [J].
LAMPUGNANI, MG ;
RESNATI, M ;
DEJANA, E ;
MARCHISIO, PC .
JOURNAL OF CELL BIOLOGY, 1991, 112 (03) :479-490
[10]   INTEGRINS AS DYNAMIC REGULATORS OF VASCULAR FUNCTION [J].
LUSCINSKAS, FW ;
LAWLER, J .
FASEB JOURNAL, 1994, 8 (12) :929-938